As of Oct 15, 2026, Abridge's estimated valuation is $6.3B; its last round was a Series E on Jun 12, 2025, raising $309.5M at a $5.3B valuation.
Estimated Valuation$6.3B
Valuation As OfOct 15, 2026
Latest Raise$309.5M
Latest RoundSeries E
Latest Funding Valuation$5.3B
Latest Funding DateJun 12, 2025
About Abridge
Abridge is a healthcare AI company that uses generative AI to transcribe and summarize doctor-patient conversations, automatically generating clinical notes to reduce physicians' paperwork burden.
Funding rounds
| Round | |||
|---|---|---|---|
| Jun 12, 2025 | Series E | $309.5M | $5.3B |
| Nov 14, 2024 | Series D | $293.2M | $2.75B |
| Feb 22, 2024 | Series C | $153.49M | $850M |
| Jun 27, 2023 | Series B | $32.5M | $216.12M |
| Aug 11, 2022 | Series A-1 | $12.5M | $144.48M |
| Mar 14, 2022 | Series A-1 | $19M | - |
| Mar 26, 2020 | Series A | $10.16M | $102.98M |
| Jan 31, 2019 | Series Seed | $5.32M | $26.59M |
Perpetual markets
No perpetual markets available.
Token issuers
No token issuer markets available.
Frequently asked questions
What is Abridge's estimated valuation?
As of Oct 15, 2026, Abridge's latest tracked valuation estimate is $6.3B.
When was Abridge's last funding round?
Abridge's latest tracked funding round was a Series E on Jun 12, 2025, raising $309.5M at a $5.3B valuation.
Valuation and funding data updated Oct 16, 2026, 10:56 PM UTC.
Market data updated Oct 16, 2026, 10:56 PM UTC.